个性化质量改进:解决心房动中的抗凝血缺口
概括
许多被发现有抗凝血缺陷的心房患者不需要治疗. 一项由药剂师主导的审查证实了大多数明显的差距都得到了解释,突出了对质量指标的潜在高估.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 心房动显著增加了中风风险.
- 抗凝固疗法是有效的,但在符合条件的患者中未得到充分利用,这表明护理质量差距.
- 一个由药剂师领导的质量改善计划旨在解决这些抗凝治疗缺口.
研究的目的:
- 识别,验证和关闭患有心房动的患者明显的抗凝治疗缺口.
- 评估自动化算法在检测抗凝治疗缺陷方面的准确性.
主要方法:
- 包括患有心房的成人初级保健患者,CHA2DS2-VASc分数至少为2,目前没有使用抗凝剂.
- 使用索赔和电子健康记录数据来识别患者.
- 图表审查和提供者推广被用来验证和解释明显的治疗差距.
主要成果:
- 在有明显缺陷的242名患者中,有84%的患者确实有治疗缺陷.
- 然而,86%的验证差距是由诸如自发AF解决,患者拒绝,手术或高出血风险等因素解释的.
- 药剂师审查和提供者推广解决了大多数已识别的机会.
结论:
- 仅依赖索赔和电子健康记录数据的自动化算法可以显著高估抗凝治疗缺口.
- 彻底的验证过程对于准确评估抗凝管理中的质量指标至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
Errors occurring during blood pressure monitoring
601
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
601
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468
Clot Retraction and Fibrinolysis
4.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.0K


